Skip to content

Effect of Dialysis Techniques on Blood Pressure and Cardiac Function During Dialysis

Effect of High-volume Online hemodiafiLtration on Intra-diaLytic hemodynAmic (iN)sTability and Cardiac Function in Chronic Hemodialysis Patients (the HOLLANT Study)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03249532
Acronym
HOLLANT
Enrollment
40
Registered
2017-08-15
Start date
2018-06-01
Completion date
2021-02-15
Last updated
2021-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diastolic Dysfunction, End Stage Renal Disease (ESRD), Hemodiafiltration, Hemodialysis, Intradialytic Hypotension

Brief summary

Online hemodiafiltration confers a reduced mortality risk. However, it is not clear why HDF improved survival. To gain more insight in this issue, the effect of 4 dialysis techniques (differing in dialysate temperature and the absence/presence of convective clearance) on intradialytic hemodynamic stability and cardiac function will be investigated in a prospective cross over trial.

Detailed description

Despite the use of high permeable dialyzers, which combine diffusive with convective clearance, the clinical outcome of hemodialysis (HD) patients remains poor. In post-dilution online hemodiafiltration (denoted further on as HDF) diffusive clearance is similar to HD, while the amount of convective transport is considerable increased. Recently, 4 randomized controlled trails have been published which compared HD with HDF. Although the results of the individual studies were inconclusive, a recent meta-analysis, using individual patient data of these studies, showed a superior outcome for patients treated with HDF. The largest mortality reduction was obtained in patients receiving the highest convection volume (high-volume HDF \[HV-HDF\] \>23 L/1.73 m2/session): all-cause mortality \[22% (95 % confidence interval \[CI\] 2-38)\], cardiovascular disease (CVD) mortality \[31% (95 % CI 0-53)\]. It is far from clear, however, why (HV)HDF is associated with an improved survival. Both long term and short term effects may be involved. With respect to the latter, the intra-dialytic removal of middle molecular weight (MMW) uremic retention products and a superior bio-incompatibility (BI) profile may play a role. In addition, treatment with HDF may induce less intra-dialytic hypotension (IDH) and less tissue injury. Enhanced removal of the MMW substance FGF23 may reduce the intra-dialytic acute phase reaction (APR), which is regarded a chief element of HD-induced BI. Other key components which may contribute to IDH and are supposed to be alleviated by HDF, include dialysis-induced hypoxia and intra-dialytic extracellular vesicle release. Patho-physiologically, IDH depends both on a decline in the circulating blood volume and an impaired response to hypovolaemia. As a result, venous return, cardiac output and peripheral vascular resistance are impaired. Since IDH is reduced by HD with cool dialysate (C-HD), thermal factors may play an important role. Microcirculatory dysfunction is a prominent feature of HD patients. Since IDH occurs in 20-30% of the sessions, any interference with an already abnormal perfusion may further deteriorate the structure and function of vital organs, such as the brain, gut and heart. HD-associated cardiomyopathy, which is considered a model of repetitive organ ischemia-reperfusion injury, is superimposed on the cardiac changes resulting from the various inflammatory and metabolic derangements of pre-dialysis kidney disease. As measured by imaging techniques and biomarkers, HD induces a fall in cardiac perfusion and elicits tissue injury. While cardiac MRI is considered the reference method for LV quantification, intra-dialytic measurements can only be obtained in stable patients who can be safely transferred to the radiology department. Echocardiography, though, can be performed in all individuals at the bed-side, including hypotension-prone patients. Because of its superiority over standard echocardiography, especially with respect to diastolic (dys)function, speckle tracking echocardiography will be used in the present study. As mentioned, the effect on long term survival is especially prominent when HV-HDF is applied. Theoretically, HV-HDF is also the preferred treatment to circumvent dialysis-induced IDH, and hence, to alleviate the repetitive intra-dialytic tissue damage. Therefore, the following hypotheses will be tested: 1. intra-dialytic hemodynamic stability is better preserved during HV-HDF as compared to standard (S)-HD, C-HD and low volume (LV)-HDF; 2. mainly as a result of a better intra-dialytic hemodynamic stability, the severity of organ injury, especially the heart, is least evident during HV-HDF; 3. the mechanism of a better preserved intra-dialytic hemodynamic stability during HV-HDF depends on its superior thermal balance and/or bio-incompatibility, clearance of MMW substances, or a combination of these items. Worldwide, however, (HV)HDF is only limited available. Since intradialytic hemodynamic instability may contribute substantially to the poor clinical prospects of end-stage-kidney-disease (ESKD) patients, these individuals may benefit from each maneuver that minimizes the number and severity of intradialytic hypotensive episodes. Therefore, the question which of the comparator treatments \[(S)-HD, C-HD and LV-HDF\] has the best intradialytic hemodynamic stability, appears relevant as well.

Interventions

hemodialysis with high-flux dialyzer; prescription of dialysate temperature: 36.5 degrees Celsius; convection volume: not applicable

DEVICEcool hemodialysis

hemodialysis with high-flux dialyzer; prescription of dialysate temperature: 35.5 degrees Celsius; convection volume: not applicable

DEVICElow volume hemodiafiltration

hemodiafiltration; prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 15 L

DEVICEhigh volume hemodiafiltration

hemodiafiltration; prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 25 L

Sponsors

Niercentrum aan de Amstel, Amstelveen, Netherlands
CollaboratorUNKNOWN
B.Braun Avitum AG
CollaboratorINDUSTRY
Amsterdam UMC, location VUmc
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Masking description

treatment period will not be available to the assessors of secondary outcomes.

Intervention model description

prospective, cross over, randomized order

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* treatment with HD or HDF 3 x per week during at least 4 hours for at least 2 months * ability to understand study procedures * willingness to provide informed consent * single pool Kt/V urea (spKt/Vurea) ≥ 1.2 * achievement of blood flow of ≥360 ml/min and/or convection volume of \>23 Liter per treatment during the run-in phase

Exclusion criteria

* \- current age \< 18 years * severe incompliance to dialysis procedure and accompanying prescriptions, especially frequency and duration of dialysis treatment * life expectancy \< 3 months * participation in another clinical intervention trial

Design outcomes

Primary

MeasureTime frameDescription
intradialytic hypotensionup to 4 hours (= one dialysis treatment); assessed during 3 treatments on each modalitynadir in systolic blood pressure (SBP) of 90 mmHg for patient with predialysis SBP \<160mmHg and a nadir of 100 mmHg for patients with predialysis SBP ≥160 mmHg during treatment (blood pressure will be measured before and every 15 minutes after the start of dialysis during the treatment)

Secondary

MeasureTime frameDescription
diastolic dysfunction during treatmentup to 4 hours (= one dialysis treatment); assessed during 1 treatment on each modalityspeckle tracking echocardiography will be performed before, after 60 minutes of dialysis and after and after 3,5 hours

Other

MeasureTime frameDescription
diastolic blood pressureup to 4 hours(= one dialysis treatment); assessed during 3 treatments on each modalitychange in diastolic blood pressure (mmHg)
mean arterial blood pressureup to 4 hours(= one dialysis treatment); assessed during 3 treatments on each modalitychange in mean arterial blood pressure (mmHg)
beat-to-beat blood pressureup to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modalitychange in beat-to-beat blood pressure (finger cuff; mmHg)
heart rateup to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modalitychange in heart rate (finger cuff assessment)
stroke volumeup to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modalitychange in stroke volume (finger cuff assessment)
cardiac outputup to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modalitychange in cardiac output (finger cuff assessment)
total peripheral resistanceup to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modalitychange in total peripheral resistance (finger cuff assessment)
number of sessions with reached target dry weightup to 4 hours(= one dialysis treatment); assessed during 3 treatments on each modalitynumber of sessions with reached target dry weight (kg)
relative blood volumeup to 4 hours(= one dialysis treatment); assessed during 2 treatments on each modalityrelative blood volume (%) during dialysis treatment
pulse pressureup to 4 hours(= one dialysis treatment); assessed during 3 treatments on each modalitychange in pulse pressure (systolic - diastolic blood pressure; mmHg)
oxygen partial pressure (pO2)up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modalitypO2 in the arterial line of the extracorporeal system (mmHg or kiloPascal \[kPa\], assessed by a point of care device) during dialysis treatment; patients with central venous catheters and fistulas/grafts will be analyzed separately
change in creatine kinase (CK)-MBup to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modalitymarker of cardiac damage, assessment in blood from arterial line of extracorporeal circuit, before and after dialysis treatment
change in bacterial DNA in bloodup to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modalitymarker of gut ischemia, assessment in blood from arterial line of extracorporeal circuit, before and after dialysis treatment
change in soluble CD14up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modalitymarker of gut ischemia, assessment in blood from arterial line of extracorporeal circuit, before and after dialysis treatment
change in extracellular vesicles (EVs)up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modalitymarker of endothelial damage, assessment in blood from arterial line of extracorporeal circuit, before and after dialysis treatment
change in soluble intercellular adhesion molecule-1 (s-ICAM-1)up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modalitymarker of endothelial damage, assessment in blood from arterial line of extracorporeal circuit, before and after dialysis treatment
change in high sensitivity C-reactive protein (hs-CRP)up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modalitymarker of inflammation, assessment in blood from arterial line of extracorporeal circuit, before and after dialysis treatment
change in interleukin-6 (IL-6)up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modalitymarker of inflammation, assessment in blood from arterial line of extracorporeal circuit, before and after dialysis treatment
change in fibroblast growth factor-23 (FGF-23)up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modalitymarker of inflammation/mineral bone disease, assessment in blood from arterial line of extracorporeal circuit, before and after dialysis treatment
oxygen saturationup to 4 hours(= one dialysis treatment); assessed during 2 treatments on each modalityoxygen saturation in the arterial line of the extracorporeal system (%) during dialysis treatment; patients with central venous catheters and fistulas/grafts will be analyzed separately
systolic blood pressureup to 4 hours(= one dialysis treatment); assessed during 3 treatments on each modalitychange in systolic blood pressure (mmHg)

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 23, 2026